Mr. Speaker, as I indicated earlier, drug-resistant infections cost a tremendous amount to the health care system. I think that these are clinical decisions made by doctors and that is their decision, is to not over-prescribe a certain drug into the system due to the fact that the virus or infection may be able to build up an immunity to that drug, then that is something that the department will follow. These decisions are clinical and then we try to take the advice of clinicians. Thank you.
Tom Beaulieu on Question 174-17(3): Preventative Measures For MRSA Infections
In the Legislative Assembly on October 17th, 2012. See this statement in context.
Question 174-17(3): Preventative Measures For MRSA Infections
Oral Questions
October 16th, 2012
Tu Nedhe
See context to find out what was said next.